Heparin induced thrombocytopenia: Diagnosis and contemporary antithrombin management

Journal of Thrombosis and Thrombolysis

Volumn 7, Issue 3, 1999, Pages 259-264

  Januzzi Jr , James L ^a   Jang, Ik Kyung ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antithrombin; Argatroban; Heparin; HIT; r hirudin; Thrombocytopenia

Indexed keywords

ANCROD; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; ARGATROBAN; DANAPAROID; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

BLEEDING; DRUG HYPERSENSITIVITY; GANGRENE; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY TEST; MORBIDITY; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOSIS;

ANCROD; CHONDROITIN SULFATES; DERMATAN SULFATE; DRUG COMBINATIONS; FIBRINOLYTIC AGENTS; FORECASTING; GANGRENE; HEMORRHAGE; HEPARIN; HEPARITIN SULFATE; HIRUDIN THERAPY; HIRUDINS; HUMANS; PIPECOLIC ACIDS; PLATELET AGGREGATION; PROTEIN C; RECOMBINANT PROTEINS; THROMBIN; THROMBOCYTOPENIA; WARFARIN;

EID: 0032997930     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008979010033     Document Type: Review

References (28)

1. Cancio LC, Cohen DJ. Heparin-induced thrombocytopenia and thrombosis. J Am Coll Surg 1998;186:76-91.
2. Greinacher A, Amiral J, Dummel V, Vissac A, Kiefel V, Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994;34:381-385.
3. Warkentin TE, Kelton JG. A 14 year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-507.
4. Singer RL, Mannion JD, Bauer TL, Armenti FR, Edie RN. Complications from HIT in patients undergoing cardiopulmonary bypass. Chest 1993;104:1436-1440.
5. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
6. Jackson MR, Krishnamurti C, Aylesworth CA, Alving BM. Diagnosis of heparin-induced thrombocytopenia in the vascular surgery patient. Surgery 1997;121:419-424.
7. 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1995;104:648-654.
8. Tomer A. A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. Br J Hematol 1997;98:648-656.
9. Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. Ann Intern Med 1997;127:804-812.
10. Weitz J, Hirsh J. New anticoagulant strategies. J Clin Lab Med 1993;122:364-373.
11. George JN, Alving B, Ballem P. Platelets. In: McArthur JR, Benz EJ, eds. Hematology - 1994: The Educational Program of the American Society of Hematology. Washington, DC: The American Society of Hematology, 1994:66-68.
12. Slocum MM, Adams JG, Teel R, Spadone DP, Silver D. Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome. J Vasc Surg 1996;23:839-843.
13. Brennan MB, MacKean GL. Heparin-induced thrombosis treated with ancrod. Can J Surg 1994;37:161-164.
14. Lathan LO, Staggers SL. Ancrod: The use of snake venom in the treatment of patients with heparin-induced thrombocytopenia and thrombosis undergoing coronary artery bypass grafting. Heart Lung 1996;25:451-460.
15. Wilde MI, Markham A. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 1997;54:903-924.
16. Magnani HN. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran (Org 10172). Thromb Hemost 1993;70:554-561.
17. Weitz JI,Califf RM, Ginsberg JS, Hirsh J, Theroux P. New antithrombotics. Chest 1995;108:471S-485S.
18. Potzsch B, Madlener K, Seelig C, Riess CP, Greinacher A, Mueller-Berhaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - assessment of the whole blood ecarin clotting time. Thromb Hemost 1997;77:920-925.
19. Lewis BE, Walenga J, Wallis DE. Anticoagulation with Novastan® (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost 1997;23: 197-202.
20. Matsuo T, Kario K, Chikahira Y, Nakao K, Yamada T. Treatment of HIT by use of argatroban, a synthetic thrombin inhibitor. Br J Hematol 1992;82:627-629.
21. Lefevre G, Duval M, Gauron S, et al. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin. Clin Pharmacol Ther 1997;62:50-59.
22. Esslinger HU, Haas S, Maurer R, Lassman A, Dubbers K, Muller-Peltzer H. Pharmacodynamic and safety results of PEG-hirudin in healthy volunteers. Thromb Hemost 1997; 77:911-919.
23. Scheile P, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, Bassand JP. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 1995;50:20-25.
24. Greinacher A, Volpel H, Potzsch B. Recombinant hirudin in the treatment of patients with heparin-associated thrombocytopenia type II (HIT), (abstr). Blood 1996;88(Suppl. 1): 281a.
25. Chamberlin JR, Lewis B, Leya P, et al. Successful treatment of heparin-associated thrombocytopenia and thrombosis using hirulog. Can J Cardiol 1995;11:511-514.
26. Kappa JR, Fisher CA, Addonizio VP. Efficacy of iloprost in preventing heparin-induced platelet activation during cardiac surgery. In: Roque Pifarre, ed. New Anticoagulants for the Cardiovascular Patient Philadelphia: Hanley and Belfus: 1997:501-516.
27. Fergusen TJ. Meeting highlights: The 1995 European Society of Cardiology. Circulation 1995;92:2359-2363.
28. Aster RH. Heparin induced thrombocytopenia and thrombosis. N Engl J Med 1995;332:1374-1376.